An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 May 2016
At a glance
- Drugs GSK 3532795 (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 11 May 2016 Status changed from recruiting to discontinued.
- 08 Dec 2015 Planned End Date changed from 1 Jan 2018 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
- 08 Dec 2015 Planned primary completion date changed from 1 Jan 2018 to 1 Nov 2017 as reported by ClinicalTrials.gov record.